Table 4– Pooled estimates of test accuracy in subgroups stratified by different factors
Studies nSensitivity (95% CI) %I2 %p-valueSpecificity (95% CI) %I2 %p-value
Urine preparation#
 Fresh359 (53–64)95.4<0.000189 (85–92)0.00.9
 Frozen649 (22–77)97.3<0.000197 (89–99)93.3<0.0001
Test version
 Noncommercial282 (76–88)39.80.287 (85–89)62.30.1
 Chemogen+545 (26–66)95.1<0.000194 (82–98)88.9<0.0001
 Alere¶,§240 (35–46)98.7<0.000198 (95–99)61.60.1
  • Estimates were calculated using bivariate random effects models, preferentially using data excluding clinical cases (analysis A), otherwise using strict microbiological reference standards (analysis B). I2: inconsistency. #: if urine was frozen before lipoarabinomannan testing was performed, it was considered “frozen” whether processing of urine was done before or after freezing; : univariate random effects regression performed because too few studies to converge bivariate model; +: Chemogen Inc., Portland, ME, USA; §: Alere Inc. (formerly Inverness Medical Innovations Inc.), Waltham, MA, USA.